Susquehanna International Group
ZVSA

Susquehanna International Group’s ZyVersa Therapeutics ZVSA Stock Holding History

Susquehanna International Group’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39
Closed -$1.77K – 13443
2023
Q3 		$1.77K Buy
+39
New +$2.32K ﹤0.01% 11850

Other funds holding ZVSA

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's ZVSA Position: Q4 2023 in Review

Susquehanna International Group sold out of ZyVersa Therapeutics (ZVSA) in Q4 2023, closing a stake of 39 shares — an estimated $1.77K sold.

Susquehanna International Group first reported a position in ZVSA in Q3 2023 and held it in 1 quarter. The position peaked at $1.77K in Q3 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q4 2023.

  • Susquehanna International Group reported no remaining ZyVersa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 39 ZyVersa Therapeutics shares in Q4 2023, an estimated $1.77K.
  • Susquehanna International Group first reported a position in ZyVersa Therapeutics in Q3 2023 and held it in 1 quarter.
  • Susquehanna International Group's ZyVersa Therapeutics position peaked at $1.77K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.